Search Results - "Powderly J"

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours.

Authors: Powderly, J. Bendell, J.C. Carneiro, B.A. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS728-S729. 2p.

596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours.

Authors: Powderly, J. Shimizu, T. Lorusso, P. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS499-S499. 1p.

438PSafety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891.

Authors: Powderly, J Cassier, P A Cervantes, A et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors.

Authors: Melero, I. Lakhani, N.J. Powderly, J. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS709-S710. 2p.

922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Authors: Song, Z. Park, J. Zhang, Y. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS603-S603. 1p.

1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Berger, R. Tolcher, A.W. Dorff, T.B. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1000-S1001. 2p.

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion.

Authors: Shenderov, E. Mallesara, G.H.G. Wysocki, P.J. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS657-S659. 3p.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.

Authors: Colevas, A D Bahleda, R Braiteh, F et al.

Source: Annals of Oncology. Nov2018, Vol. 29 Issue 11, p2247-2253. 7p. 4 Charts, 2 Graphs.

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors.

Authors: Marron, T. Segar, J. Berlin, J.D. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS523-S523. 1p.

163P Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors.

Authors: Bar, J. Sharma, M.R. Kuboki, Y. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS246-S247. 2p.

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors.

Authors: Marron, T.U. Misleh, J.G. C. chen et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS623-S624. 2p.

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors.

Authors: Ku, G. Shen, L. Klempner, S.J. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS631-S631. 1p.

1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy.

Authors: Starodub, A.N. Kim, S-B. Davar, D. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS628-S628. 1p.

1137PDIdentification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444.

Authors: Willingham, S Hotson, A N Laport, G et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Authors: Sharma MR Powderly J Kuboki Y et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 10; Vol. 44 (20), pp. 1956. Date of Electronic Publication: 2026 Jun 15.

Publication Type: Journal Article; Published Erratum

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Authors: Sharma MR Powderly J Kuboki Y et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 10; Vol. 44 (20), pp. 1876-1888. Date of Electronic Publication: 2026 May 01.

Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.

Authors: Shenderov E Sharma MR Garralda E et al.

Source: Cancer [Cancer] 2026 Aug 01; Vol. 132 (15), pp. e70544.

Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Authors: Shimizu T Powderly J Abdul Razak A et al.

Source: Frontiers in oncology [Front Oncol] 2025 Jan 31; Vol. 14, pp. 1544394. Date of Electronic Publication: 2025 Jan 31 (Print Publication: 2024).

Publication Type: Published Erratum

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Authors: Ku G Shen L Dayyani F et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4944-4952.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Authors: Shimizu T Powderly J Abdul Razak A et al.

Source: Frontiers in oncology [Front Oncol] 2024 Oct 29; Vol. 14, pp. 1376551. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE